Signition LP Purchases Shares of 3,764 Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Signition LP acquired a new stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,764 shares of the biopharmaceutical company’s stock, valued at approximately $369,000. Alexion Pharmaceuticals makes up approximately 1.5% of Signition LP’s portfolio, making the stock its 22nd biggest holding.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Steward Partners Investment Advisory LLC acquired a new position in shares of Alexion Pharmaceuticals during the second quarter valued at about $28,000. Redhawk Wealth Advisors Inc. acquired a new position in shares of Alexion Pharmaceuticals during the second quarter valued at about $29,000. Investors Research Corp increased its holdings in shares of Alexion Pharmaceuticals by 52.0% during the third quarter. Investors Research Corp now owns 304 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 104 shares in the last quarter. Ossiam acquired a new position in shares of Alexion Pharmaceuticals during the second quarter valued at about $32,000. Finally, Capital Bank & Trust Co increased its holdings in shares of Alexion Pharmaceuticals by 355.9% during the second quarter. Capital Bank & Trust Co now owns 269 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 210 shares in the last quarter. Hedge funds and other institutional investors own 94.68% of the company’s stock.

Several equities analysts recently weighed in on the stock. TheStreet downgraded shares of Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Thursday, August 15th. Leerink Swann set a $157.00 price target on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Robert W. Baird set a $165.00 price target on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 30th. Raymond James increased their price target on shares of Alexion Pharmaceuticals from $168.00 to $170.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. Finally, ValuEngine upgraded shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 2nd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fifteen have assigned a buy rating to the company’s stock. Alexion Pharmaceuticals has an average rating of “Buy” and a consensus price target of $159.00.

Shares of NASDAQ ALXN traded down $1.81 during midday trading on Monday, reaching $108.98. 94,505 shares of the stock were exchanged, compared to its average volume of 1,803,421. The firm has a market cap of $23.73 billion, a price-to-earnings ratio of 15.37, a PEG ratio of 1.02 and a beta of 1.65. Alexion Pharmaceuticals, Inc. has a twelve month low of $92.56 and a twelve month high of $141.86. The firm has a 50-day simple moving average of $102.45 and a two-hundred day simple moving average of $115.69. The company has a quick ratio of 3.45, a current ratio of 3.98 and a debt-to-equity ratio of 0.25.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 EPS for the quarter, topping analysts’ consensus estimates of $2.47 by $0.32. The business had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.24 billion. Alexion Pharmaceuticals had a net margin of 31.05% and a return on equity of 21.21%. The business’s revenue was up 23.0% on a year-over-year basis. During the same quarter last year, the company earned $2.02 EPS. Research analysts expect that Alexion Pharmaceuticals, Inc. will post 9.41 EPS for the current fiscal year.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Featured Article: Using the New Google Finance Tool

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.